
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7180484/publications.pdf Version: 2024-02-01



FUZABETH FOX

#	Article	IF	CITATIONS
1	Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. Neuro-Oncology, 2022, 24, 655-664.	1.2	24
2	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. European Journal of Cancer, 2022, 160, 112-133.	2.8	24
3	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i> /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. Journal of Clinical Oncology, 2022, 40, 2023-2035.	1.6	36
4	Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial. Journal of Clinical Oncology, 2022, 40, 2224-2234.	1.6	45
5	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. Journal of Clinical Oncology, 2022, 40, 2235-2245.	1.6	21
6	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i> , <i>ROS1</i> , or <i>ALK</i> aberrations (STARTRK-NG). Neuro-Oncology, 2022, 24, 1776-1789.	1.2	37
7	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. European Journal of Cancer, 2022, 166, 145-164.	2.8	28
8	Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. Neuro-Oncology Advances, 2022, 4, .	0.7	2
9	ADVL1514, a phase 1 study of ABI-009 (nab-sirolimus) in pediatric patients with recurrent or refractory solid tumors, including CNS tumors as a single agent and in combination with temozolomide and irinotecan: A Children's Oncology Group pediatric early-phase clinical trial network study Journal of Clinical Oncology. 2022. 40. 10022-10022.	1.6	1
10	Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J) Journal of Clinical Oncology, 2022, 40, 3009-3009.	1.6	5
11	Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C) Journal of Clinical Oncology, 2022, 40, 10009-10009.	1.6	5
12	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. European Journal of Cancer, 2022, 173, 71-90.	2.8	9
13	Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope, 2021, 131, E1941-E1949.	2.0	24
14	A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phaseâ€Clinical Trial Network (PEPâ€CTN). Pediatric Blood and Cancer, 2021, 68, e28892.	1.5	16
15	NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. JCO Precision Oncology, 2021, 1, 204-214.	3.0	36
16	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clinical Cancer Research, 2021, 27, 3543-3548.	7.0	59
17	Bromodomain and extra-terminalÂinhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE. European Journal of Cancer, 2021, 146, 115-124.	2.8	10
18	A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. Cancer Chemotherapy and Pharmacology, 2021, 87, 807-815.	2.3	3

#	Article	IF	CITATIONS
19	A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatric Blood and Cancer, 2021, 68, e29065.	1.5	16
20	Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615) Journal of Clinical Oncology, 2021, 39, 10019-10019.	1.6	2
21	Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. Cancer Chemotherapy and Pharmacology, 2021, 88, 359-365.	2.3	7
22	Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712 Journal of Clinical Oncology, 2021, 39, 10018-10018.	1.6	0
23	Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols Journal of Clinical Oncology, 2021, 39, 10007-10007.	1.6	2
24	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	1.5	3
25	Population Pharmacokinetics and Exposureâ€Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. Journal of Clinical Pharmacology, 2021, , .	2.0	3
26	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European Journal of Cancer, 2021, 157, 198-213.	2.8	34
27	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. Blood, 2021, 138, 3679-3679.	1.4	4
28	Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates. Journal of Circulating Biomarkers, 2021, 10, 26-29.	1.3	2
29	The ganglioside G _{D2} as a circulating tumor biomarker for neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28031.	1.5	30
30	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric Blood and Cancer, 2020, 67, e28073.	1.5	52
31	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncology, The, 2020, 21, 121-133.	10.7	204
32	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncology, The, 2020, 21, 271-282.	10.7	1,034
33	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. European Journal of Cancer, 2020, 139, 135-148.	2.8	20
34	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemotherapy and Pharmacology, 2020, 86, 829-840.	2.3	22
35	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcomaâ€"A Children's Oncology Group study. Cancer, 2020, 126, 5303-5310.	4.1	17
36	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncology, The, 2020, 21, 541-550.	10.7	202

#	Article	IF	CITATIONS
37	Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clinical Cancer Research, 2020, 26, 4743-4747.	7.0	0
38	Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research, 2020, 26, 1213-1219.	7.0	38
39	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. Blood, 2020, 136, 20-21.	1.4	5
40	Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors Journal of Clinical Oncology, 2020, 38, 107-107.	1.6	15
41	Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results Journal of Clinical Oncology, 2020, 38, 10506-10506.	1.6	11
42	How to address challenges and opportunities in pediatric cancer drug development?. Expert Opinion on Drug Discovery, 2020, 15, 869-872.	5.0	1
43	Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 707-717.	2.3	2
44	3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials. Journal of Clinical and Translational Science, 2019, 3, 30-31.	0.6	0
45	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research, 2019, 25, 3229-3238.	7.0	61
46	PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. Neuro-Oncology, 2019, 21, vi186-vi186.	1.2	0
47	Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors Journal of Clinical Oncology, 2019, 37, 10009-10009.	1.6	49
48	Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial Journal of Clinical Oncology, 2019, 37, 10011-10011.	1.6	25
49	Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615) Journal of Clinical Oncology, 2019, 37, e21521-e21521.	1.6	1
50	A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614) Journal of Clinical Oncology, 2019, 37, e21519-e21519.	1.6	3
51	Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. Oncologist, 2018, 23, 762-e79.	3.7	28
52	Phase 1 trial of ontuxizumab (MORAbâ€004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatric Blood and Cancer, 2018, 65, e26944.	1.5	19
53	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research, 2018, 24, 753-765.	7.0	26
54	PDCT-04. PHASE 1 TRIAL OF WEE1 KINASE INHIBITOR AZD1775 COMBINED WITH RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE CHILDREN' ONCOLOGY GROUP PHASE 1 PILOT CONSORTIUM (ADVL1217). Neuro-Oncology, 2018, 20, vi201-vi201.	S1.2	3

#	Article	IF	CITATIONS
55	New Agents, Emerging Late Effects, and the Development of Precision Survivorship. Journal of Clinical Oncology, 2018, 36, 2231-2240.	1.6	44
56	A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer, 2018, 124, 4548-4555.	4.1	35
57	A phase 1 study of eribulin mesylate (E7389), a novel microtubuleâ€ŧargeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatric Blood and Cancer, 2018, 65, e27066.	1.5	15
58	Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study Journal of Clinical Oncology, 2018, 36, 10504-10504.	1.6	35
59	KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma Journal of Clinical Oncology, 2018, 36, 10525-10525.	1.6	10
60	Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN) Journal of Clinical Oncology, 2018, 36, 10537-10537.	1.6	20
61	G _{D2} as a circulating tumor biomarker (CTB) for neuroblastoma (NBL) Journal of Clinical Oncology, 2018, 36, 10538-10538.	1.6	2
62	Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas Journal of Clinical Oncology, 2018, 36, 10542-10542.	1.6	4
63	ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors Journal of Clinical Oncology, 2018, 36, 10556-10556.	1.6	6
64	A phase 1 study of the câ€Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatric Blood and Cancer, 2017, 64, e26565.	1.5	11
65	Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. Pediatric Blood and Cancer, 2017, 64, e26636.	1.5	23
66	First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemotherapy and Pharmacology, 2017, 79, 181-187.	2.3	28
67	Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope, 2017, 127, 1538-1542.	2.0	47
68	Historical time to disease progression and progressionâ€free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group earlyâ€phase trials. Cancer, 2017, 123, 4914-4923.	4.1	108
69	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2017, 23, 6062-6069.	7.0	7
70	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. Journal of Clinical Oncology, 2017, 35, 3215-3221.	1.6	315
71	Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1 ⁺ advanced, relapsed, or refractory solid tumor or lymphoma Journal of Clinical Oncology, 2017, 35, 10525-10525.	1.6	11
72	Overcoming resistance to single-agent therapy for oncogenic <i>BRAF</i> gene fusions <i>via</i> combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget, 2017, 8, 84697-84713.	1.8	38

#	Article	IF	CITATIONS
73	Effect of infusion duration on high-dose methotrexate (HDMTX) acute kidney injury (AKI) Journal of Clinical Oncology, 2017, 35, e22013-e22013.	1.6	0
74	15-0600-Dr. Fox's response to letter to the editor. Cancer Chemotherapy and Pharmacology, 2016, 78, 1099-1100.	2.3	0
75	Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. International Journal of Pediatric Endocrinology (Springer), 2015, 2015, 3.	1.6	10
76	Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1562-1566.	1.5	63
77	Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 76, 1273-1283.	2.3	48
78	A 6-Year-Old With Leg Cramps. Pediatrics, 2015, 136, 732-739.	2.1	0
79	Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Children's Oncology Group study Journal of Clinical Oncology, 2015, 33, 10029-10029.	1.6	2
80	An Integrated Service Delivery Model to Identify Persons Living with HIV and to Provide Linkage to HIV Treatment and Care in Prioritized Neighborhoods: A Geotargeted, Program Outcome Study. JMIR Public Health and Surveillance, 2015, 1, e16.	2.6	7
81	Time to disease progression in children with relapsed or refractory neuroblastoma treated with <scp>ABT</scp> â€751: A report from the Children's Oncology Group (ANBL0621). Pediatric Blood and Cancer, 2014, 61, 990-996.	1.5	16
82	A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 971, 30-34.	2.3	1
83	Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients Journal of Clinical Oncology, 2014, 32, 10034-10034.	1.6	3
84	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors Journal of Clinical Oncology, 2014, 32, 10052-10052.	1.6	1
85	A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children's Oncology Group phase I consortium trial Journal of Clinical Oncology, 2014, 32, 10078-10078.	1.6	1
86	A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children's Oncology Group study Journal of Clinical Oncology, 2014, 32, 2627-2627.	1.6	3
87	Prospective assessment of renal function using cystatin C and functional MRI in children with newly diagnosed renal tumors Journal of Clinical Oncology, 2014, 32, 10053-10053.	1.6	Ο
88	Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Clinical Cancer Research, 2013, 19, 4239-4248.	7.0	136
89	Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist, 2012, 17, 321-e329.	3.7	100
90	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study Journal of Clinical Oncology, 2012, 30, 9500-9500.	1.6	29

#	Article	IF	CITATIONS
91	Pharmacokinetics (PK) of the chimericÂanti-G _{D2} antibody, ch14.18, in children with high-risk neuroblastoma Journal of Clinical Oncology, 2012, 30, 9576-9576.	1.6	Ο
92	The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. Journal of Neuroimmunology, 2010, 223, 138-140.	2.3	44
93	A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. Journal of Clinical Oncology, 2010, 28, 5174-5181.	1.6	98
94	Commentary. Clinical Chemistry, 2010, 56, 1795-1795.	3.2	0